Trifarotene 0.005% Cream: A Novel Topical Retinoid as a Monotherapy in Mild to Moderate Facial Acne Vulgaris in Egyptian patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202510658002240

Enrollment

Registered

2025-10-28

Start date

2024-12-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases

Interventions

Trifarotene cream

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Age 12 years or older. - Both sexes. - Clinical diagnosis of mild or moderate acne vulgaris.

Exclusion criteria

Exclusion criteria: - History of using systemic or topical treatment for at least 3 months. - Pregnant or lactating females. - Any systemic diseases. - Allergy to any drug.

Design outcomes

Primary

Measure	Time frame
Investigator Global Assessment [IGA]	—

Secondary

Measure	Time frame
Subjective Satisfaction Scale;Local tolerability parameter;Incidence of adverse events	—

Countries

Egypt

Contacts

Public ContactNoura El Seessy

Lecturer

Nora_Elsiesy@med.kfs.edu.eg00201000117186

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026